CINXE.COM

<!DOCTYPE html><html><head><meta charSet="utf-8"/><link rel="icon" type="image/svg+xml" href="/favicon.svg"/><link rel="alternate" type="application/rss+xml" title="Investor News Feed from Synairgen" href="/feed/investor-news"/><meta name="viewport" content="width=device-width, initial-scale=1.0, viewport-fit=cover"/><title>Breakthrough Science for Severe Viral Lung Infections - Synairgen</title><meta name="description" content="Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. Discover SNG001, our breakthrough treatment for COVID-19."/><meta property="og:type" content="website"/><meta property="og:title" content="Breakthrough Science for Severe Viral Lung Infections - Synairgen"/><meta property="og:image" content=""/><meta property="og:image:width" content="1200"/><meta property="og:image:height" content="630"/><meta property="og:description" content="Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. Discover SNG001, our breakthrough treatment for COVID-19."/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="Breakthrough Science for Severe Viral Lung Infections - Synairgen"/><meta name="twitter:description" content="Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. Discover SNG001, our breakthrough treatment for COVID-19."/><meta name="twitter:image" content=""/><link rel="preconnect" crossorigin="true" href="https://i.ytimg.com/"/><link rel="preconnect" crossorigin="true" href="https://i.ytimg.com/"/><meta name="next-head-count" content="18"/><link rel="preload" href="/_next/static/css/d6170faf7287777f.css" as="style"/><link rel="stylesheet" href="/_next/static/css/d6170faf7287777f.css" data-n-g=""/><link rel="preload" href="/_next/static/css/051efe0b17edacf9.css" as="style"/><link rel="stylesheet" href="/_next/static/css/051efe0b17edacf9.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-5cd94c89d3acac5f.js"></script><script src="/_next/static/chunks/webpack-e443416cc051def9.js" defer=""></script><script src="/_next/static/chunks/framework-01395af778c6fb71.js" defer=""></script><script src="/_next/static/chunks/main-2b659c3a39c747d2.js" defer=""></script><script src="/_next/static/chunks/pages/_app-3578c125f087b268.js" defer=""></script><script src="/_next/static/chunks/935-b8ce6d58fefe9a6e.js" defer=""></script><script src="/_next/static/chunks/675-b9e4539e8c0434c4.js" defer=""></script><script src="/_next/static/chunks/333-4f6e5fb17ac94e01.js" defer=""></script><script src="/_next/static/chunks/pages/index-f844ea1a556bf5cd.js" defer=""></script><script src="/_next/static/-x01IBkAo6htgTgKAvdde/_buildManifest.js" defer=""></script><script src="/_next/static/-x01IBkAo6htgTgKAvdde/_ssgManifest.js" defer=""></script><script src="/_next/static/-x01IBkAo6htgTgKAvdde/_middlewareManifest.js" defer=""></script></head><body><div id="__next" data-reactroot=""><header class="style_header__5q4mN"><a class="style_logo__Ekr0u" href="/"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" width="150" height="40" viewBox="0 0 150 40"><defs><path id="logo_svg__a" d="M0 0h14.276v21.128H0z"></path><path id="logo_svg__c" d="M0 0h21.295v31.693H0z"></path><path id="logo_svg__e" d="M0 0h16.975v20.668H0z"></path></defs><g fill="none" fill-rule="evenodd"><g transform="translate(0 8.308)"><mask id="logo_svg__b" fill="#fff"><use xlink:href="#logo_svg__a"></use></mask><path fill="#1F4A77" d="M6.773 18.464c1.921 0 3.89-.872 3.89-2.618 0-1.698-2.518-2.848-4.713-4.179C3.982 10.471.962 9.14.962 5.557.962 2.892 3.112 0 7.32 0c3.48 0 5.218.92 6.36 1.47l-1.052 2.435c-.913-.459-2.47-1.287-5.262-1.287-1.782 0-2.973.92-2.973 2.39 0 1.652 2.014 2.478 4.348 3.857 1.785 1.01 5.535 2.847 5.535 6.2 0 3.767-3.523 6.063-7.137 6.063-4.392 0-6.177-1.102-7.14-1.423l1.01-2.527c.822.367 3.11 1.286 5.764 1.286" mask="url(#logo_svg__b)"></path></g><path fill="#1F4A77" d="M24.124 34.121c-1.282 2.94-2.884 5.876-6.314 5.878-2.303.002-3.25-.716-3.25-.716v-3.075c-.533-.196 1.557.805 3.02.805 2.242 0 3.25-2.57 4.117-4.41l1.465-3.352L14.56 8.767h4.165l6.312 15.753 5.63-15.753h3.612L24.124 34.12Zm24.7-5.145v-13.64c0-2.113-.73-3.951-3.2-3.951-2.654 0-5.172 1.745-6.178 2.39v15.201h-3.797V8.767h3.614l.09 2.25c1.009-.642 3.477-2.708 7.504-2.708 3.936 0 5.81 2.434 5.765 6.199v14.468h-3.797Z"></path><path fill="#006AAC" d="M66.484 24.798c-1.005.733-2.47 1.836-4.39 1.836-2.379.046-3.707-1.103-3.707-2.94 0-2.112 1.648-3.766 5.26-4.134l2.837-.228v5.466Zm3.753 1.01V13.956c0-3.17-1.785-5.648-6.177-5.648-4.025 0-6.632 1.33-7.687 1.927l.962 2.068c.777-.32 2.791-1.33 5.536-1.33 3.11 0 3.613 2.017 3.613 3.81v2.435l-4.253.137c-5.079.368-7.503 3.49-7.503 6.706 0 3.307 2.241 5.374 5.947 5.374 2.699 0 4.85-1.471 5.856-2.251 0 .459.183 1.24.412 1.792h4.027c-.32-.598-.687-2.16-.733-3.17Zm8.175-23.42C78.412 1.146 77.27 0 76.034 0s-2.379 1.147-2.379 2.387c0 1.287 1.144 2.388 2.38 2.388 1.234 0 2.377-1.101 2.377-2.388Zm-4.254 26.59h3.797V8.767h-3.797v20.21Zm7.474-.002V8.767h3.433l.18 3.628c.733-1.057 2.838-4.086 5.492-4.086 1.692 0 2.698.917 3.34 1.422l-1.555 2.71c-.64-.505-1.19-.826-2.518-.826-2.287 0-3.98 2.755-4.575 3.675v13.686h-3.797Z"></path><g transform="translate(91.89 8.307)"><mask id="logo_svg__d" fill="#fff"><use xlink:href="#logo_svg__c"></use></mask><path fill="#1F4A77" d="M9.884 28.982c-3.89 0-6.407-1.194-6.498-3.307-.09-2.755 2.837-4.41 3.934-5.005h6.087c2.242 0 4.483.733 4.21 3.628-.276 2.848-4.667 4.684-7.733 4.684m.412-26.502c2.928 0 4.161 2.16 4.161 3.996 0 2.068-1.37 3.904-4.16 3.904-2.655 0-4.12-1.836-4.12-3.904 0-1.836 1.465-3.996 4.12-3.996m4.16 14.881H8.511c-1.557 0-3.798-.274-3.798-2.25 0-1.836 2.47-2.25 3.89-2.25h1.967c4.116 0 7.596-2.572 7.596-6.385 0-1.836-1.008-3.077-1.465-3.582h4.392V.461h-7.642C12.674.277 12.033 0 9.837 0c-4.895 0-7.32 3.17-7.32 6.476 0 3.032 1.51 4.227 2.47 4.777-1.007.277-3.659 1.884-3.659 4.87 0 2.755 1.785 3.856 2.652 4.27-1.463.735-3.98 2.48-3.98 5.743.046 5.052 6.497 5.557 10.157 5.557 4.027 0 10.067-1.839 11.027-7.211.732-4.18-2.242-7.12-6.727-7.12" mask="url(#logo_svg__d)"></path></g><path fill="#1F4A77" d="M121.79 10.88c2.561 0 4.573 1.975 4.71 5.466h-9.652c.32-2.985 1.966-5.466 4.942-5.466m-5.035 8.084h13.774c0-7.442-3.936-10.655-8.74-10.655-5.307 0-9.15 4.914-9.15 10.655 0 6.476 3.567 10.47 9.744 10.47 4.134-.01 5.822-1.286 6.828-1.84v-3.116c-1.345.888-2.894 2.284-6.049 2.248-4.073-.046-6.407-2.664-6.407-7.762"></path><g transform="translate(133.025 8.309)"><mask id="logo_svg__f" fill="#fff"><use xlink:href="#logo_svg__e"></use></mask><path fill="#1F4A77" d="M13.177 20.668V7.028c0-2.114-.732-3.952-3.2-3.952-2.655 0-5.172 1.745-6.18 2.39v15.202H0V.458h3.614l.092 2.25C4.714 2.066 7.183 0 11.21 0c3.936 0 5.812 2.434 5.765 6.199v14.469h-3.797Z" mask="url(#logo_svg__f)"></path></g></g></svg></a><nav><ul class="style_nav__OelYl"><li><a href="/">Home</a></li><li><a href="/about">About +</a><div class="style_subNav__2Uc4b"><ul><li><a href="/about">Our Story</a></li><li><a href="/about/team">Meet the Team</a></li><li><a href="/faqs">FAQs</a></li></ul></div></li><li><a href="/science">Our Science +</a><div class="style_subNav__2Uc4b"><ul><li><a href="/science">Inhaled IFN-β</a></li><li><a href="/science/programmes">Clinical Trials</a></li><li><a href="/ifn-beta-publication-list">Publications</a></li></ul></div></li><li><a href="/investors">Investors +</a><div class="style_subNav__2Uc4b"><ul><li><a href="/investors/performance">Share Price Information</a></li><li><a href="/investors/presentations">Reports & Presentations</a></li><li><a href="/investors/investor-news">Investor News</a></li><li><a href="/investors/analysts">Shareholder Information</a></li><li><a href="/investors/aim-rule-26">AIM Rule 26</a></li><li><a href="/investors/corporate-governance-statement">Corporate Governance</a></li><li><a href="/investors/investor-calendar">Investor Calendar</a></li></ul></div></li><li><a href="/media">News +</a><div class="style_subNav__2Uc4b"><ul><li><a href="/media#press">Press Releases</a></li><li><a href="/media/resources">Resources</a></li><li><a href="/media/resources#factsheets">Factsheets</a></li><li><a href="/investors/tr1">TR-1/Options Press Releases</a></li></ul></div></li><li><a href="/careers">Careers</a></li><li><a href="/contact">Contact</a></li><li><button title="Search" class="style_btn__1TfQR"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><g fill="none" fill-rule="evenodd" stroke="#002158" stroke-linecap="round" stroke-linejoin="round" stroke-width="1.5"><path d="M1.8 11.187a7.158 7.158 0 1 0 13.175-5.6 7.158 7.158 0 0 0-13.175 5.6ZM13.448 13.448 19 19"></path></g></svg></button></li></ul></nav><button class="style_toggle__kqCub"></button><div class="style_mobileNav__bBprb"><div class="style_blobs__K_iOE style_blobs__Ee9UP style_small__BMeag"><span class="style_blob__1JQDk"></span><span class="style_blob__1JQDk"></span><span class="style_blob__1JQDk"></span></div><a class="style_logo__Kpo8P" href="/"><svg xmlns="http://www.w3.org/2000/svg" width="150" height="40" viewBox="0 0 150 40"><g fill="#FFF" fill-rule="evenodd"><path d="M6.773 26.772c1.921 0 3.89-.873 3.89-2.618 0-1.699-2.518-2.848-4.713-4.18C3.982 18.78.962 17.449.962 13.865c0-2.664 2.15-5.556 6.358-5.556 3.48 0 5.218.919 6.36 1.47l-1.052 2.434c-.913-.458-2.47-1.286-5.262-1.286-1.782 0-2.973.919-2.973 2.39 0 1.651 2.014 2.478 4.348 3.857 1.785 1.01 5.535 2.846 5.535 6.2 0 3.767-3.523 6.063-7.137 6.063-4.392 0-6.177-1.103-7.14-1.424l1.01-2.527c.822.368 3.11 1.287 5.764 1.287m17.35 7.349c-1.28 2.94-2.883 5.876-6.313 5.878-2.303.002-3.25-.716-3.25-.716v-3.075c-.533-.196 1.557.805 3.02.805 2.242 0 3.25-2.57 4.117-4.41l1.465-3.352L14.56 8.767h4.165l6.312 15.753 5.63-15.753h3.612L24.124 34.12Zm24.702-5.145v-13.64c0-2.113-.73-3.951-3.202-3.951-2.653 0-5.171 1.745-6.177 2.39v15.201h-3.797V8.767h3.614l.09 2.25c1.009-.642 3.477-2.708 7.504-2.708 3.936 0 5.81 2.434 5.765 6.199v14.468h-3.797Zm17.66-4.178c-1.006.733-2.472 1.836-4.39 1.836-2.38.046-3.708-1.103-3.708-2.94 0-2.112 1.648-3.766 5.26-4.134l2.837-.228v5.466Zm3.752 1.01V13.956c0-3.17-1.785-5.648-6.177-5.648-4.025 0-6.632 1.33-7.687 1.927l.962 2.068c.777-.32 2.791-1.33 5.536-1.33 3.11 0 3.613 2.017 3.613 3.81v2.435l-4.253.137c-5.079.368-7.503 3.49-7.503 6.706 0 3.307 2.241 5.374 5.947 5.374 2.699 0 4.85-1.471 5.856-2.251 0 .459.183 1.24.412 1.792h4.027c-.32-.598-.687-2.16-.733-3.17Zm8.175-23.42C78.412 1.146 77.27 0 76.034 0s-2.379 1.147-2.379 2.387c0 1.287 1.144 2.388 2.38 2.388 1.234 0 2.377-1.101 2.377-2.388Zm-4.254 26.59h3.797V8.767h-3.797v20.21Zm7.474-.002V8.767h3.433l.18 3.628c.733-1.057 2.838-4.086 5.492-4.086 1.692 0 2.698.917 3.34 1.422l-1.555 2.71c-.64-.505-1.19-.826-2.518-.826-2.287 0-3.98 2.755-4.575 3.675v13.686h-3.797Zm20.141 8.313c-3.89 0-6.407-1.193-6.497-3.306-.09-2.755 2.837-4.41 3.933-5.006h6.087c2.242 0 4.483.733 4.21 3.628-.276 2.848-4.667 4.684-7.733 4.684m.413-26.501c2.927 0 4.16 2.16 4.16 3.995 0 2.069-1.37 3.905-4.16 3.905-2.654 0-4.12-1.836-4.12-3.905 0-1.836 1.466-3.995 4.12-3.995m4.16 14.88h-5.945c-1.558 0-3.8-.274-3.8-2.25 0-1.836 2.472-2.25 3.89-2.25h1.968c4.117 0 7.596-2.571 7.596-6.385 0-1.836-1.008-3.076-1.465-3.581h4.392V8.768h-7.642c-.776-.184-1.418-.46-3.613-.46-4.896 0-7.32 3.169-7.32 6.475 0 3.032 1.509 4.228 2.47 4.777-1.008.277-3.66 1.885-3.66 4.87 0 2.756 1.785 3.857 2.652 4.27-1.462.736-3.98 2.48-3.98 5.743.046 5.052 6.498 5.557 10.157 5.557 4.027 0 10.067-1.838 11.027-7.21.733-4.18-2.241-7.121-6.726-7.121"></path><path d="M121.79 10.88c2.561 0 4.573 1.975 4.71 5.466h-9.652c.32-2.985 1.966-5.466 4.942-5.466m-5.035 8.084h13.774c0-7.442-3.936-10.655-8.74-10.655-5.307 0-9.15 4.914-9.15 10.655 0 6.476 3.567 10.47 9.744 10.47 4.134-.01 5.822-1.286 6.828-1.84v-3.116c-1.345.888-2.894 2.284-6.049 2.248-4.073-.046-6.407-2.664-6.407-7.762m29.447 10.012v-13.64c0-2.113-.732-3.951-3.2-3.951-2.655 0-5.172 1.745-6.18 2.39v15.201h-3.797V8.767h3.614l.092 2.25c1.008-.642 3.477-2.708 7.503-2.708 3.936 0 5.812 2.434 5.765 6.199v14.468h-3.797Z"></path></g></svg></a><nav class="style_nav__eXj7F"><ul class="style_active__9qXOV"><li><a href="/">Home</a></li><li><a href="/about">About</a><button><svg xmlns="http://www.w3.org/2000/svg" width="12" height="21" viewBox="0 0 12 21"><path fill="#FFF" d="M11.437 10.54a.753.753 0 0 0-.07-.326.98.98 0 0 0-.196-.274L1.81 1.02a.817.817 0 0 0-.585-.228.806.806 0 0 0-.694.389.793.793 0 0 0-.107.412c0 .217.074.406.223.566l8.816 8.38L.646 18.92a.802.802 0 0 0-.223.566.783.783 0 0 0 .4.695c.123.07.257.106.4.106.231 0 .427-.08.586-.24l9.362-8.908a.97.97 0 0 0 .197-.276c.046-.1.07-.207.07-.324Z" opacity="0.5"></path></svg></button></li><li><a href="/science">Our Science</a><button><svg xmlns="http://www.w3.org/2000/svg" width="12" height="21" viewBox="0 0 12 21"><path fill="#FFF" d="M11.437 10.54a.753.753 0 0 0-.07-.326.98.98 0 0 0-.196-.274L1.81 1.02a.817.817 0 0 0-.585-.228.806.806 0 0 0-.694.389.793.793 0 0 0-.107.412c0 .217.074.406.223.566l8.816 8.38L.646 18.92a.802.802 0 0 0-.223.566.783.783 0 0 0 .4.695c.123.07.257.106.4.106.231 0 .427-.08.586-.24l9.362-8.908a.97.97 0 0 0 .197-.276c.046-.1.07-.207.07-.324Z" opacity="0.5"></path></svg></button></li><li><a href="/investors">Investors</a><button><svg xmlns="http://www.w3.org/2000/svg" width="12" height="21" viewBox="0 0 12 21"><path fill="#FFF" d="M11.437 10.54a.753.753 0 0 0-.07-.326.98.98 0 0 0-.196-.274L1.81 1.02a.817.817 0 0 0-.585-.228.806.806 0 0 0-.694.389.793.793 0 0 0-.107.412c0 .217.074.406.223.566l8.816 8.38L.646 18.92a.802.802 0 0 0-.223.566.783.783 0 0 0 .4.695c.123.07.257.106.4.106.231 0 .427-.08.586-.24l9.362-8.908a.97.97 0 0 0 .197-.276c.046-.1.07-.207.07-.324Z" opacity="0.5"></path></svg></button></li><li><a href="/media">News</a><button><svg xmlns="http://www.w3.org/2000/svg" width="12" height="21" viewBox="0 0 12 21"><path fill="#FFF" d="M11.437 10.54a.753.753 0 0 0-.07-.326.98.98 0 0 0-.196-.274L1.81 1.02a.817.817 0 0 0-.585-.228.806.806 0 0 0-.694.389.793.793 0 0 0-.107.412c0 .217.074.406.223.566l8.816 8.38L.646 18.92a.802.802 0 0 0-.223.566.783.783 0 0 0 .4.695c.123.07.257.106.4.106.231 0 .427-.08.586-.24l9.362-8.908a.97.97 0 0 0 .197-.276c.046-.1.07-.207.07-.324Z" opacity="0.5"></path></svg></button></li><li><a href="/careers">Careers</a></li><li><a href="/contact">Contact</a></li></ul><ul class=""><li><button><svg xmlns="http://www.w3.org/2000/svg" width="12" height="21" viewBox="0 0 12 21"><path fill="#FFF" d="M11.437 10.54a.753.753 0 0 0-.07-.326.98.98 0 0 0-.196-.274L1.81 1.02a.817.817 0 0 0-.585-.228.806.806 0 0 0-.694.389.793.793 0 0 0-.107.412c0 .217.074.406.223.566l8.816 8.38L.646 18.92a.802.802 0 0 0-.223.566.783.783 0 0 0 .4.695c.123.07.257.106.4.106.231 0 .427-.08.586-.24l9.362-8.908a.97.97 0 0 0 .197-.276c.046-.1.07-.207.07-.324Z" opacity="0.5"></path></svg> Back</button></li><li><a href="/about">Our Story</a></li><li><a href="/about/team">Meet the Team</a></li><li><a href="/faqs">FAQs</a></li></ul><ul class=""><li><button><svg xmlns="http://www.w3.org/2000/svg" width="12" height="21" viewBox="0 0 12 21"><path fill="#FFF" d="M11.437 10.54a.753.753 0 0 0-.07-.326.98.98 0 0 0-.196-.274L1.81 1.02a.817.817 0 0 0-.585-.228.806.806 0 0 0-.694.389.793.793 0 0 0-.107.412c0 .217.074.406.223.566l8.816 8.38L.646 18.92a.802.802 0 0 0-.223.566.783.783 0 0 0 .4.695c.123.07.257.106.4.106.231 0 .427-.08.586-.24l9.362-8.908a.97.97 0 0 0 .197-.276c.046-.1.07-.207.07-.324Z" opacity="0.5"></path></svg> Back</button></li><li><a href="/science">Inhaled IFN-β</a></li><li><a href="/science/programmes">Clinical Trials</a></li><li><a href="/ifn-beta-publication-list">Publications</a></li></ul><ul class=""><li><button><svg xmlns="http://www.w3.org/2000/svg" width="12" height="21" viewBox="0 0 12 21"><path fill="#FFF" d="M11.437 10.54a.753.753 0 0 0-.07-.326.98.98 0 0 0-.196-.274L1.81 1.02a.817.817 0 0 0-.585-.228.806.806 0 0 0-.694.389.793.793 0 0 0-.107.412c0 .217.074.406.223.566l8.816 8.38L.646 18.92a.802.802 0 0 0-.223.566.783.783 0 0 0 .4.695c.123.07.257.106.4.106.231 0 .427-.08.586-.24l9.362-8.908a.97.97 0 0 0 .197-.276c.046-.1.07-.207.07-.324Z" opacity="0.5"></path></svg> Back</button></li><li><a href="/investors/performance">Share Price Information</a></li><li><a href="/investors/presentations">Reports & Presentations</a></li><li><a href="/investors/investor-news">Investor News</a></li><li><a href="/investors/analysts">Shareholder Information</a></li><li><a href="/investors/aim-rule-26">AIM Rule 26</a></li><li><a href="/investors/corporate-governance-statement">Corporate Governance</a></li><li><a href="/investors/investor-calendar">Investor Calendar</a></li></ul><ul class=""><li><button><svg xmlns="http://www.w3.org/2000/svg" width="12" height="21" viewBox="0 0 12 21"><path fill="#FFF" d="M11.437 10.54a.753.753 0 0 0-.07-.326.98.98 0 0 0-.196-.274L1.81 1.02a.817.817 0 0 0-.585-.228.806.806 0 0 0-.694.389.793.793 0 0 0-.107.412c0 .217.074.406.223.566l8.816 8.38L.646 18.92a.802.802 0 0 0-.223.566.783.783 0 0 0 .4.695c.123.07.257.106.4.106.231 0 .427-.08.586-.24l9.362-8.908a.97.97 0 0 0 .197-.276c.046-.1.07-.207.07-.324Z" opacity="0.5"></path></svg> Back</button></li><li><a href="/media#press">Press Releases</a></li><li><a href="/media/resources">Resources</a></li><li><a href="/media/resources#factsheets">Factsheets</a></li><li><a href="/investors/tr1">TR-1/Options Press Releases</a></li></ul></nav></div></header><header class="style_hero__CAS46 style_tall__fSOq2"><div class="style_blobs__K_iOE "><span class="style_blob__1JQDk"></span><span class="style_blob__1JQDk"></span><span class="style_blob__1JQDk"></span></div><section id="" class="style_wrap__qjPVe "><div class="style_container__sgRJ7 style_content__M598h style_grid__piEkS style_alignEnd__aNuxU"><figure class="style_image___wokw"><img src="https://synairgen.ams3.digitaloceanspaces.com/synairgen-lung-illustration.svg"/></figure><div class="style_text__aOkrO"><div><h1>Breakthrough Science for Severe Viral Lung Infections</h1><p>We are a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta (IFN-β) for the treatment of severe viral lung infections as potentially the first host-directed, broad-spectrum antiviral treatment delivered directly into the lungs.</p><footer class="style_btnGroup___hsE2 "><a rel="" class="style_btn__g6gfm style_large__i2IFl" href="https://synairgen.vercel.app/science">Our Science</a><a rel="" class="style_btn__g6gfm style_medium__4XQfK style_text__ZymPQ" href="/about">Our Story</a></footer></div></div></div></section></header><section class="style_videoGrid__u2cMQ"><header><h2>Not All Antivirals Are the Same</h2><div class="style_prose__woZCM "><h3>Host Directed, broad-spectrum antivirals<br/></h3> <p><strong>Host Directed</strong> is Synairgen's new podcast series that explores the need for broad-spectrum antivirals to treat severe respiratory infections. In Episode 1, <em>Not All Antivirals Are the Same</em>, Professor Tom Wilkinson from the University of Southampton and Vicki Tear, Vice President, Non-Clinical Operations, Synairgen, discuss how antiviral agents work on viruses and the potential benefits of broad-spectrum host-directed antivirals. Episode 2 includes Professor Ratko Djukanovic, Professor of Medicine at University of Southampton and Richard Marsden, CEO of Synairgen, continuing the discussion with a focus on understanding the broad-spectrum antiviral protein, IFN-β.</p></div></header><div class="style_videos__bKji_"><figure><div class="style_video__sUzrG style_video__o62gq"><div><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%271160%27%20height=%27652.5%27/%3e"/></span><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" srcSet="/_next/image?url=https%3A%2F%2Fsynairgen.ams3.digitaloceanspaces.com%2F_2320x1305_crop_center-center_none%2Fhost-directed-ep-1.jpg&w=1200&q=75 1x, /_next/image?url=https%3A%2F%2Fsynairgen.ams3.digitaloceanspaces.com%2F_2320x1305_crop_center-center_none%2Fhost-directed-ep-1.jpg&w=3840&q=75 2x" src="/_next/image?url=https%3A%2F%2Fsynairgen.ams3.digitaloceanspaces.com%2F_2320x1305_crop_center-center_none%2Fhost-directed-ep-1.jpg&w=3840&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span><div class="style_play__U91MU"><span></span></div></div></div><figcaption><div class="style_prose__woZCM "><p>Episode 1: Not All Antivirals Are the Same</p> <p>Professor Tom Wilkinson from the University of Southampton and Vicki Tear, Vice President, Non-Clinical Operations, Synairgen, discuss how antiviral agents work on viruses and the potential benefits of broad-spectrum host-directed antivirals.</p></div></figcaption></figure><figure><div class="style_video__sUzrG style_video__o62gq"><div><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%271160%27%20height=%27652.5%27/%3e"/></span><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" srcSet="/_next/image?url=https%3A%2F%2Fsynairgen.ams3.digitaloceanspaces.com%2F_2320x1305_crop_center-center_none%2FSynairgen-HD-Podcast2.jpg&w=1200&q=75 1x, /_next/image?url=https%3A%2F%2Fsynairgen.ams3.digitaloceanspaces.com%2F_2320x1305_crop_center-center_none%2FSynairgen-HD-Podcast2.jpg&w=3840&q=75 2x" src="/_next/image?url=https%3A%2F%2Fsynairgen.ams3.digitaloceanspaces.com%2F_2320x1305_crop_center-center_none%2FSynairgen-HD-Podcast2.jpg&w=3840&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span><div class="style_play__U91MU"><span></span></div></div></div><figcaption><div class="style_prose__woZCM "><p>Episode 2: What is IFN-β and How Does It Work?</p> <p>Professor Ratko Djukanovic, Professor of Medicine at University of Southampton and Richard Marsden, CEO of Synairgen, continue to explore antivirals with a discussion focused on understanding the broad-spectrum antiviral protein, IFN-β .</p></div></figcaption></figure></div></section><section id="" class="style_wrap__qjPVe style_wrap__w6_1K"><div class="style_container__sgRJ7 "><div class="style_content__sC_Nt"><h2>The Need</h2><div class="style_prose__woZCM style_large__PW8R1"><p>Viruses that cause severe respiratory infections (VRIs) lead to the hospitalisation of more than 3 million people in the US alone each year.</p></div><span></span><div class="style_prose__woZCM "><p>There are currently no broad-spectrum antivirals approved for use in patients who become hospitalised with these sRVIs including SARS-CoV-2, complicated influenza, RSV, adenovirus, parainfluenza and rhinoviruses.</p> <p><sub>source: IQVIA</sub></p></div></div><ul class="style_stats___roIF"><li><i><svg width="48px" height="52px" viewBox="0 0 48 52" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><title>hospital</title><g id="Q4—2022" stroke="none" stroke-width="1" fill="none" fill-rule="evenodd"><g id="Home" transform="translate(-870.000000, -2308.000000)" stroke="#0160FD" stroke-width="3"><g id="hospital" transform="translate(872.000000, 2310.000000)"><polygon id="Path" points="0 18.0488795 22.0000238 0 44 18.0488795 44 48 0 48"></polygon><line x1="32.6163853" y1="29.2540988" x2="11.3831872" y2="29.2540988" id="Path"></line><line x1="22.0002613" y1="39.9709065" x2="22.0002613" y2="18.5371472" id="Path"></line></g></g></g></svg></i><h4>Estimated 3m+</h4><p>people in US hospitalised annually from 2022 onwards due to severe VRIs</p><small>source: IQVIA market research Q4 2022; Sources: US CDC, HCUP, IQVIA Claims Data, PubMed; data on file</small></li><li><i><svg width="52px" height="50px" viewBox="0 0 52 50" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><title>lungs</title><g id="Q4—2022" stroke="none" stroke-width="1" fill="none" fill-rule="evenodd"><g id="Home" transform="translate(-1199.000000, -2310.000000)" stroke="#0160FD" stroke-width="3"><g id="lungs" transform="translate(1201.002512, 2310.000000)"><path d="M0.000445025429,43.7897796 C-0.0439200106,44.9518565 3.24098418,48.0846853 4.39939856,47.9850826 L16.6363357,46.7327534 C17.7363436,46.6037025 20.356048,43.1496118 20.1838789,42.0553036 L19.0757934,34.4912349 C18.1436938,28.1280108 17.4536619,21.7362614 17.0056976,15.3159868 C16.9406957,13.950183 12.3528409,11.3403905 11.145991,11.9827038 C3.13063018,16.5683161 0.403195515,27.438534 0.000445025429,43.7897796 Z" id="Path"></path><polyline id="Path" points="23.9985312 0 23.9985312 17.7413311 6.26081533 31.3082314"></polyline><line x1="12.1726917" y1="26.7852356" x2="8.34760544" y2="22.9593697" id="Path"></line><line x1="10.4156144" y1="28.1294023" x2="12.5211856" y2="33.3954468" id="Path"></line><polyline id="Path" points="10.4343955 36.52627 12.5211856 33.3954468 14.6079757 34.4390545"></polyline><path d="M36.8510715,11.9827038 C44.8768662,16.5745777 47.5938669,27.438534 47.9945306,43.7897796 C48.0388956,44.9518565 44.7539915,48.0846853 43.5955771,47.9850826 L31.3586399,46.7327534 C30.2586321,46.6037025 27.6389277,43.1496118 27.8110967,42.0553036 L28.9191823,34.4912349 C29.8512819,28.1280108 30.5413138,21.7362614 30.9892781,15.3159868 C31.0539371,13.9495635 35.6440611,11.3394096 36.8510715,11.9827038 Z" id="Path"></path><line x1="23.9985312" y1="17.7413311" x2="41.7362471" y2="31.3082314" id="Path"></line><line x1="35.8243707" y1="26.7852356" x2="39.649457" y2="22.9593697" id="Path"></line><line x1="37.581448" y1="28.1294023" x2="35.4758768" y2="33.3954468" id="Path"></line><polyline id="Path" points="37.5626669 36.52627 35.4758768 33.3954468 33.3890867 34.4390545"></polyline></g></g></g></svg></i><h4>7m immuno-compromised</h4><p>in the US, representing a population at significant risk for severe RVIs</p><small>source: American Medical Association</small></li><li><i><svg width="28px" height="52px" viewBox="0 0 28 52" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><title>dollar</title><g id="Q4—2022" stroke="none" stroke-width="1" fill="none" fill-rule="evenodd"><g id="Home" transform="translate(-706.000000, -2367.000000)" stroke="#0160FD" stroke-width="3"><g id="dollar" transform="translate(708.000000, 2369.000000)"><path d="M0,34.79688 L0,38.29992 C0,41.00616 2.350512,43.2 5.25,43.2 L18.75,43.2 C21.64944,43.2 24,41.00832 24,38.30232 L24,29.30784 C24,27.13008 22.45992,25.21416 20.22,24.60432 L3.780024,20.12904 C1.540032,19.5192 0,17.602992 0,15.425208 L0,9.69972 C0,6.993504 2.350488,4.8 5.249976,4.8 L18.75,4.8 C21.64944,4.8 24,6.993816 24,9.700008 L24,13.204656" id="Path"></path><line x1="12" y1="48" x2="12" y2="0" id="Path" stroke-linecap="square"></line></g></g></g></svg></i><h4>$50b</h4><p>The estimated annual US healthcare costs related to severe VRIs</p><small>sources: Hartnet J. Influenza Other Respi Viruses. 2022;16:906–915; Pastula ST et.al.,OFID, 2017,ofw270; Zhou JA et.al., CID, 2020, 70(5): 773-779; Disease Burden of Flu | CDC; Preliminary Medicare COVID-19 Data Snapshot (Dec 2021); ICER Report: Special Assessment of Outpatient Treatments for COVID-19 Feb 2022</small></li></ul></div></section><section id="" class="style_wrap__qjPVe style_quotesWrap__sQuGn"><div class="style_container__sgRJ7 "><div class="style_blobs__K_iOE style_blobs__VgB5O"><span class="style_blob__1JQDk"></span><span class="style_blob__1JQDk"></span><span class="style_blob__1JQDk"></span></div><div class="style_quotes__tT4_y"><blockquote class="style_active__Za6ri"><p><svg xmlns="http://www.w3.org/2000/svg" width="38" height="26" viewBox="0 0 38 26"><path fill="#0160FD" d="M14.2.56H7.36C2.68 8.12.76 10.16.76 14v11.52H14.2V12.08H10c-1.2 0-1.68.12-2.52.48-.72.36-1.68.72-1.92 0s.36-.96 1.68-1.68c.48-.24 1.2-.96 1.44-1.44L14.2.56Zm23.04 0H30.4c-4.68 7.56-6.6 9.6-6.6 13.44v11.52h13.44V12.08h-4.2c-1.2 0-1.68.12-2.52.48-.72.36-1.68.72-1.92 0s.36-.96 1.68-1.68c.48-.24 1.2-.96 1.44-1.44L37.24.56Z"></path></svg>It Ain’t Over Till It’s Over…but It’s Never Over<svg xmlns="http://www.w3.org/2000/svg" width="38" height="26" viewBox="0 0 38 26"><path fill="#0160FD" d="M14.2.56H7.36C2.68 8.12.76 10.16.76 14v11.52H14.2V12.08H10c-1.2 0-1.68.12-2.52.48-.72.36-1.68.72-1.92 0s.36-.96 1.68-1.68c.48-.24 1.2-.96 1.44-1.44L14.2.56Zm23.04 0H30.4c-4.68 7.56-6.6 9.6-6.6 13.44v11.52h13.44V12.08h-4.2c-1.2 0-1.68.12-2.52.48-.72.36-1.68.72-1.92 0s.36-.96 1.68-1.68c.48-.24 1.2-.96 1.44-1.44L37.24.56Z"></path></svg></p><cite>Dr. Anthony Fauci, New England Journal of Medicine, 26 November 2022</cite></blockquote></div><div class="style_pips___SQwu"><button type="button" class="style_active__Za6ri"></button></div></div></section><section id="" class="style_wrap__qjPVe style_deck__VQ_fM"><div class="style_container__sgRJ7 style_grid__piEkS"><header class="style_header__C_k5z"><h2>Latest News</h2></header><a class="style_mentionCard__2JF44" href="/media/exercise-of-share-options-and-total-voting-rights"><strong>Exercise of Share Options and Total Voting Rights</strong><footer><small>30th October 2024</small></footer></a><a class="style_mentionCard__2JF44" href="/media/results-of-agm-and-appointment-of-new-chairman-2"><strong>Results of AGM and Appointment of New Chairman</strong><footer><small>10th October 2024</small></footer></a><a class="style_mentionCard__2JF44" href="/media/interim-results-3"><strong>Interim Results</strong><footer><small>26th September 2024</small></footer></a></div></section><footer id="" class="style_wrap__qjPVe style_footer__IKWh6"><div class="style_container__sgRJ7 style_grid__piEkS"><nav class="style_beta__r1d8M"><ul><li>Our Science</li><li><a href="/science">Interferon Beta</a></li><li><a href="/science/covid-19">Investigating antiviral treatment in COVID-19</a></li><li><a href="/science/copd">Investigating antiviral treatment in COPD</a></li><li><a href="/science/asthma">Investigating antiviral treatment in asthma</a></li><li><a href="/ifn-beta-publication-list">Relevant Publications</a></li></ul></nav><nav class="style_nav__ztXwj"><ul><li>About</li><li><a href="/">Home</a></li><li><a href="/about">Our Story</a></li><li><a href="/about/team">Team</a></li><li><a href="/faqs">FAQs</a></li><li><a href="/careers">Careers</a></li><li><a href="/contact">Contact</a></li></ul><ul><li>Investors</li><li><a href="/investors">Investors Overview</a></li><li><a href="/investors/performance">Performance</a></li><li><a href="/investors/presentations">Reports & Presentations</a></li><li><a href="/investors/investor-news">Investor News</a></li><li><a href="/investors/analysts">Analysts</a></li><li><a href="/investors/investor-calendar">Investor Calendar</a></li></ul><ul><li>News</li><li><a href="/media#press">Press Releases</a></li><li><a href="/media/resources#factsheets">Factsheets</a></li><li><a href="/media/resources">Resources</a></li></ul></nav><div class="style_meta__DgjCn"><div class="style_logos__ITbYG"><a href="/"><svg xmlns="http://www.w3.org/2000/svg" width="150" height="40" viewBox="0 0 150 40"><g fill="#FFF" fill-rule="evenodd"><path d="M6.773 26.772c1.921 0 3.89-.873 3.89-2.618 0-1.699-2.518-2.848-4.713-4.18C3.982 18.78.962 17.449.962 13.865c0-2.664 2.15-5.556 6.358-5.556 3.48 0 5.218.919 6.36 1.47l-1.052 2.434c-.913-.458-2.47-1.286-5.262-1.286-1.782 0-2.973.919-2.973 2.39 0 1.651 2.014 2.478 4.348 3.857 1.785 1.01 5.535 2.846 5.535 6.2 0 3.767-3.523 6.063-7.137 6.063-4.392 0-6.177-1.103-7.14-1.424l1.01-2.527c.822.368 3.11 1.287 5.764 1.287m17.35 7.349c-1.28 2.94-2.883 5.876-6.313 5.878-2.303.002-3.25-.716-3.25-.716v-3.075c-.533-.196 1.557.805 3.02.805 2.242 0 3.25-2.57 4.117-4.41l1.465-3.352L14.56 8.767h4.165l6.312 15.753 5.63-15.753h3.612L24.124 34.12Zm24.702-5.145v-13.64c0-2.113-.73-3.951-3.202-3.951-2.653 0-5.171 1.745-6.177 2.39v15.201h-3.797V8.767h3.614l.09 2.25c1.009-.642 3.477-2.708 7.504-2.708 3.936 0 5.81 2.434 5.765 6.199v14.468h-3.797Zm17.66-4.178c-1.006.733-2.472 1.836-4.39 1.836-2.38.046-3.708-1.103-3.708-2.94 0-2.112 1.648-3.766 5.26-4.134l2.837-.228v5.466Zm3.752 1.01V13.956c0-3.17-1.785-5.648-6.177-5.648-4.025 0-6.632 1.33-7.687 1.927l.962 2.068c.777-.32 2.791-1.33 5.536-1.33 3.11 0 3.613 2.017 3.613 3.81v2.435l-4.253.137c-5.079.368-7.503 3.49-7.503 6.706 0 3.307 2.241 5.374 5.947 5.374 2.699 0 4.85-1.471 5.856-2.251 0 .459.183 1.24.412 1.792h4.027c-.32-.598-.687-2.16-.733-3.17Zm8.175-23.42C78.412 1.146 77.27 0 76.034 0s-2.379 1.147-2.379 2.387c0 1.287 1.144 2.388 2.38 2.388 1.234 0 2.377-1.101 2.377-2.388Zm-4.254 26.59h3.797V8.767h-3.797v20.21Zm7.474-.002V8.767h3.433l.18 3.628c.733-1.057 2.838-4.086 5.492-4.086 1.692 0 2.698.917 3.34 1.422l-1.555 2.71c-.64-.505-1.19-.826-2.518-.826-2.287 0-3.98 2.755-4.575 3.675v13.686h-3.797Zm20.141 8.313c-3.89 0-6.407-1.193-6.497-3.306-.09-2.755 2.837-4.41 3.933-5.006h6.087c2.242 0 4.483.733 4.21 3.628-.276 2.848-4.667 4.684-7.733 4.684m.413-26.501c2.927 0 4.16 2.16 4.16 3.995 0 2.069-1.37 3.905-4.16 3.905-2.654 0-4.12-1.836-4.12-3.905 0-1.836 1.466-3.995 4.12-3.995m4.16 14.88h-5.945c-1.558 0-3.8-.274-3.8-2.25 0-1.836 2.472-2.25 3.89-2.25h1.968c4.117 0 7.596-2.571 7.596-6.385 0-1.836-1.008-3.076-1.465-3.581h4.392V8.768h-7.642c-.776-.184-1.418-.46-3.613-.46-4.896 0-7.32 3.169-7.32 6.475 0 3.032 1.509 4.228 2.47 4.777-1.008.277-3.66 1.885-3.66 4.87 0 2.756 1.785 3.857 2.652 4.27-1.462.736-3.98 2.48-3.98 5.743.046 5.052 6.498 5.557 10.157 5.557 4.027 0 10.067-1.838 11.027-7.21.733-4.18-2.241-7.121-6.726-7.121"></path><path d="M121.79 10.88c2.561 0 4.573 1.975 4.71 5.466h-9.652c.32-2.985 1.966-5.466 4.942-5.466m-5.035 8.084h13.774c0-7.442-3.936-10.655-8.74-10.655-5.307 0-9.15 4.914-9.15 10.655 0 6.476 3.567 10.47 9.744 10.47 4.134-.01 5.822-1.286 6.828-1.84v-3.116c-1.345.888-2.894 2.284-6.049 2.248-4.073-.046-6.407-2.664-6.407-7.762m29.447 10.012v-13.64c0-2.113-.732-3.951-3.2-3.951-2.655 0-5.172 1.745-6.18 2.39v15.201h-3.797V8.767h3.614l.092 2.25c1.008-.642 3.477-2.708 7.503-2.708 3.936 0 5.812 2.434 5.765 6.199v14.468h-3.797Z"></path></g></svg></a><a href="https://www.hta.gov.uk/" rel="noopener noreferrer" target="_blank"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" width="106" height="47" viewBox="0 0 106 47"><defs><path id="hta_svg__a" d="M0 0h106v14.927H0z"></path><path id="hta_svg__c" d="M0 0h106v14.927H0z"></path><path id="hta_svg__e" d="M0 0h106v14.927H0z"></path><path id="hta_svg__g" d="M0 0h10.763v21.181H0z"></path><path id="hta_svg__i" d="M0 0h10.763v21.181H0z"></path></defs><g fill="none" fill-rule="evenodd" opacity="0.6"><path fill="#FFFEFE" fill-rule="nonzero" d="M24.516 15.82H28.1l-.055 7.847h8.475l.055-7.847h3.613l-.168 19.256h-3.612l.112-8.348h-8.475l-.111 8.348H24.35l.166-19.256M48.645 18.881h-5.391l.028-3.061h14.254l-.028 3.061h-5.307l-.139 16.195h-3.557l.14-16.195M66 19.549h-.056l-2.417 7.513h4.694L66 19.549Zm-5.668 15.917-3.308-1.003 7.392-18.643h3.278l6.864 18.643-3.475 1.003-1.889-5.51h-6.697l-2.165 5.51ZM24.515 39.508h.705L25.196 42h3.022l.033-2.492h.704l-.048 5.617h-.705l.024-2.54h-3.023l-.032 2.54h-.705l.049-5.617M30.284 41.084h.65l-.018 1.818c0 .356-.008.713-.008 1.111 0 .439.293.641.738.641.421 0 .794-.243 1.208-.747l.032-2.823h.648l-.032 4.04h-.648l.024-.648h-.016c-.34.487-.892.762-1.37.762-.932 0-1.232-.478-1.232-1.225 0-.308.008-.616.008-.925l.016-2.004m4.49 0h.656l-.008.591h.016c.333-.404.787-.704 1.33-.704.502 0 .908.25 1.012.746.35-.382.892-.746 1.402-.746.836 0 1.135.477 1.135 1.225 0 .308-.008.615-.008.924l-.016 2.005h-.648l.016-1.818c0-.357.008-.714.008-1.111 0-.44-.291-.642-.64-.642-.479 0-.827.293-1.15.674l-.05 2.897h-.64l.016-1.818c0-.357.008-.714.008-1.111 0-.44-.292-.642-.64-.642-.478 0-.826.293-1.15.674l-.05 2.897h-.647l.048-4.041m8.809 1.931c-1.126.145-1.71.356-1.71 1.047 0 .455.276.69.722.69.397 0 .705-.284.956-.593l.032-1.144Zm1.378 1.932c-.227.178-.47.29-.753.29-.365 0-.568-.332-.6-.672-.308.382-.697.673-1.216.673-.713 0-1.168-.487-1.168-1.168 0-1.144 1.476-1.412 2.359-1.445.008-.17.016-.34.016-.51 0-.35-.186-.61-.616-.61-.315 0-.575.114-1.166.56l-.268-.422c.81-.527 1.07-.672 1.653-.672.673 0 1.013.397 1.013 1.022 0 .763-.065 1.468-.065 2.182 0 .293.04.576.292.576.138 0 .235-.065.34-.137l.18.333Zm.64-3.863h.649l-.025.648h.017c.34-.487.89-.761 1.369-.761.932 0 1.232.477 1.232 1.225 0 .308-.01.615-.01.924l-.015 2.005h-.648l.016-1.818c0-.357.009-.714.009-1.111 0-.44-.292-.642-.738-.642-.422 0-.794.244-1.207.747l-.034 2.824h-.647l.033-4.041M50.869 39.508h4.247v.586h-1.775l-.049 5.031h-.697l.05-5.031h-1.776v-.586M55.464 41.084h.649l-.032 4.04h-.649l.032-4.04Zm-.032-.844h.696v-.732h-.696v.732Zm1.79 4.17c.228.155.544.341.892.341.357 0 .786-.194.786-.649 0-1.006-1.872-.568-1.872-1.923 0-.763.624-1.208 1.362-1.208.453 0 .875.137 1.174.34l-.299.413c-.235-.13-.486-.267-.77-.267-.47 0-.819.194-.819.673 0 .869 1.873.511 1.873 1.883 0 .771-.674 1.225-1.338 1.225-.47 0-.9-.161-1.265-.398l.276-.43m3.152 0c.227.155.543.341.892.341.357 0 .786-.194.786-.649 0-1.006-1.871-.568-1.871-1.923 0-.763.623-1.208 1.36-1.208.454 0 .876.137 1.177.34l-.3.413c-.236-.13-.487-.267-.772-.267-.47 0-.817.194-.817.673 0 .869 1.871.511 1.871 1.883 0 .771-.672 1.225-1.336 1.225-.47 0-.9-.161-1.265-.398l.275-.43m3.259-3.326h.649l-.017 1.818c0 .356-.008.713-.008 1.111 0 .439.291.641.736.641.423 0 .795-.243 1.21-.747l.032-2.823h.648l-.033 4.04h-.647l.023-.648h-.016c-.341.487-.892.762-1.37.762-.932 0-1.232-.478-1.232-1.225 0-.308.01-.616.01-.925l.015-2.004m6.937 1.493c0-.577-.244-1.12-.9-1.12-.608 0-.997.568-1.102 1.12h2.002Zm-2.059.438v.138c0 .844.316 1.598 1.143 1.598.462 0 .803-.267 1.15-.584l.317.35c-.414.414-.94.72-1.54.72-1.119 0-1.767-.81-1.767-2.133 0-1.11.762-2.133 1.848-2.133 1.085 0 1.556.827 1.556 1.915v.13H68.51Zm7.545-2.873h-.015l-.94 2.532h1.839l-.884-2.532Zm-.315-.634h.665l2.228 5.504-.697.226-.762-1.98h-2.318l-.819 1.98-.648-.202 2.351-5.528Zm3.622 1.576h.648l-.016 1.818c0 .356-.01.713-.01 1.111 0 .439.293.641.74.641.421 0 .794-.243 1.208-.747l.032-2.823h.648l-.032 4.04h-.648l.023-.648h-.017c-.339.487-.89.762-1.368.762-.932 0-1.232-.478-1.232-1.225 0-.308.008-.616.008-.925l.016-2.004m4.733 0 .016-1.493h.648l-.017 1.493h1.104v.486h-1.111l-.017 1.656c-.007.455-.007.755-.007.957 0 .334.097.519.372.519.22 0 .495-.137.649-.234l.21.422c-.267.177-.656.348-1.012.348-.624 0-.868-.39-.868-1.03 0-.269 0-.601.008-1.16l.017-1.478h-.689v-.486h.697m2.47-2.045h.674l-.032 2.678h.016c.324-.472.875-.746 1.354-.746.932 0 1.23.477 1.23 1.225 0 .308-.007.615-.007.924l-.016 2.005h-.648l.015-1.818c0-.357.01-.714.01-1.111 0-.44-.293-.642-.738-.642-.422 0-.795.244-1.208.747l-.032 2.824h-.65l.032-6.086m6.08 5.712c.607 0 1.263-.527 1.263-1.647s-.543-1.647-1.2-1.647c-.607 0-1.263.527-1.263 1.647s.543 1.647 1.2 1.647Zm.072-3.78c1.183 0 1.888.81 1.888 2.133 0 1.047-.689 2.134-1.969 2.134-1.183 0-1.887-.803-1.887-2.134 0-1.047.688-2.133 1.968-2.133Zm2.86.113h.666l-.009.787.016.016c.139-.366.535-.916 1.12-.916.136 0 .258.024.347.056l-.193.616c-.066-.016-.163-.04-.252-.04-.267 0-.697.22-1.046.868l-.032 2.654h-.65l.033-4.041m2.634 0h.65l-.032 4.04h-.65l.032-4.04Zm-.032-.844h.697v-.732h-.697v.732Z"></path><g transform="translate(0 32.073)"><mask id="hta_svg__b" fill="#fff"><use xlink:href="#hta_svg__a"></use></mask><path fill="#FFFEFE" fill-rule="nonzero" d="m100.303 9.01.017-1.492h.648l-.016 1.493h1.102v.486h-1.11l-.016 1.656c-.008.455-.008.755-.008.957 0 .334.097.519.372.519.219 0 .494-.137.65-.234l.209.422c-.268.177-.656.348-1.013.348-.624 0-.867-.39-.867-1.03 0-.269 0-.601.008-1.16l.017-1.478h-.69v-.486h.697" mask="url(#hta_svg__b)"></path><mask id="hta_svg__d" fill="#fff"><use xlink:href="#hta_svg__c"></use></mask><path fill="#FFFEFE" fill-rule="nonzero" d="M102.387 14.48c.63 0 .81-.146.98-.527l.437-.966-1.499-3.895.697-.194 1.119 3.285h.015l1.224-3.285.64.194-1.8 4.463c-.453 1.112-.688 1.413-1.554 1.413h-.26v-.489" mask="url(#hta_svg__d)"></path><mask id="hta_svg__f" fill="#fff"><use xlink:href="#hta_svg__e"></use></mask><path fill="#FFFFFE" fill-rule="nonzero" d="M1.97 1.973a6.718 6.718 0 0 1 9.513.001 6.744 6.744 0 0 1 0 9.528 6.719 6.719 0 0 1-9.513-.001 6.746 6.746 0 0 1 0-9.528" mask="url(#hta_svg__f)"></path></g><path fill="#FFFFFE" fill-rule="nonzero" d="M5.19 21.264a4.481 4.481 0 0 1 6.343 0 4.484 4.484 0 0 1 1.3 3.524 6.268 6.268 0 0 0-2.57 1.558 6.266 6.266 0 0 0-1.554 2.572 4.47 4.47 0 0 1-3.52-1.302 4.497 4.497 0 0 1 0-6.352"></path><g transform="translate(9.322 15)"><mask id="hta_svg__h" fill="#fff"><use xlink:href="#hta_svg__g"></use></mask><path fill="#FFFFFE" fill-rule="nonzero" d="M1.576 11.98a5.377 5.377 0 0 1 7.61.001 5.395 5.395 0 0 1 0 7.622 5.363 5.363 0 0 1-4.563 1.525 7.6 7.6 0 0 0-1.778-2.795A7.614 7.614 0 0 0 .053 16.55a5.385 5.385 0 0 1 1.523-4.57" mask="url(#hta_svg__h)"></path><mask id="hta_svg__j" fill="#fff"><use xlink:href="#hta_svg__i"></use></mask><path fill="#FFFFFE" fill-rule="nonzero" d="M1.576 1.184a4.032 4.032 0 0 1 5.708 0 4.046 4.046 0 0 1 0 5.716 4.024 4.024 0 0 1-3.036 1.18 5.373 5.373 0 0 0-1.403-2.45A5.353 5.353 0 0 0 .398 4.224a4.034 4.034 0 0 1 1.178-3.041" mask="url(#hta_svg__j)"></path></g><g fill="#FFF" fill-rule="nonzero"><path d="M23.768.552V9h5.376v-.864h-4.32V.552zM30.248 1.608h1.056V.36h-1.056v1.248ZM30.296 9h.96V2.856h-.96V9Zm2.112-3.072c0 1.74 1.104 3.168 2.916 3.168 1.62 0 2.556-1.128 2.652-2.304h-.936c-.12.828-.696 1.44-1.692 1.44-1.368 0-1.98-1.056-1.98-2.304 0-1.248.612-2.304 1.98-2.304.996 0 1.572.612 1.692 1.44h.936c-.096-1.176-1.044-2.304-2.652-2.304-1.848 0-2.916 1.428-2.916 3.168Zm11.904-.18c0-2.112-1.38-2.988-2.7-2.988-1.704 0-2.868 1.284-2.868 3.168 0 1.692 1.02 3.168 2.892 3.168 1.512 0 2.352-1.092 2.568-2.112h-1.008c-.216.696-.648 1.248-1.524 1.248-1.224 0-1.944-.984-1.992-2.064h4.608a3.79 3.79 0 0 0 .024-.42Zm-2.628-2.172c.96 0 1.584.696 1.668 1.824h-3.624c.132-1.008.648-1.824 1.956-1.824Zm6.876-.816c-1.104 0-1.872.828-2.124 1.428-.012.036-.06.108-.132.084-.096-.036-.036-.144 0-.24.084-.252.12-.444.12-.66v-.516h-.96V9h.96V5.94c0-1.464 1.02-2.364 1.956-2.364.852 0 1.5.396 1.5 1.824V9h.96V5.352c0-1.8-.864-2.592-2.28-2.592Zm3.24 4.128c.06 1.356 1.008 2.208 2.58 2.208 1.584 0 2.604-.756 2.604-2.004 0-.984-.912-1.44-2.364-1.62-1.572-.192-1.68-.588-1.68-.936 0-.408.372-.96 1.44-.96 1.128 0 1.44.612 1.476 1.2h.948c-.084-1.152-.888-2.016-2.388-2.016-1.584 0-2.436.972-2.436 1.896 0 .804.684 1.452 2.004 1.608 1.632.192 2.04.408 2.04 1.008 0 .396-.372 1.008-1.596 1.008-1.248 0-1.68-.732-1.692-1.392H51.8Zm11.52-1.14c0-2.112-1.38-2.988-2.7-2.988-1.704 0-2.868 1.284-2.868 3.168 0 1.692 1.02 3.168 2.892 3.168 1.512 0 2.352-1.092 2.568-2.112h-1.008c-.216.696-.648 1.248-1.524 1.248-1.224 0-1.944-.984-1.992-2.064h4.608a3.79 3.79 0 0 0 .024-.42Zm-2.628-2.172c.96 0 1.584.696 1.668 1.824h-3.624c.132-1.008.648-1.824 1.956-1.824ZM68.888.36v2.976c0 .216.024.42.108.66.036.108.108.216 0 .252-.072.024-.12-.084-.132-.12-.276-.828-1.08-1.368-2.064-1.368-1.596 0-2.712 1.344-2.712 3.168s1.116 3.168 2.712 3.168c.96 0 1.776-.528 2.064-1.392.012-.036.06-.132.144-.096.072.036.036.132 0 .228a1.68 1.68 0 0 0-.12.636V9h.96V.36h-.96Zm-1.944 7.872c-1.248 0-1.896-1.056-1.896-2.304 0-1.248.648-2.304 1.896-2.304 1.14 0 1.944 1.056 1.944 2.304 0 1.248-.804 2.304-1.944 2.304ZM75.8.36h-.96V9h.96v-.528a1.68 1.68 0 0 0-.12-.636c-.036-.096-.072-.192 0-.228.084-.036.132.06.144.096.372.828 1.104 1.392 2.064 1.392 1.596 0 2.712-1.344 2.712-3.168S79.484 2.76 77.888 2.76c-.984 0-1.704.576-2.064 1.368-.012.036-.06.144-.132.12-.108-.036-.036-.144 0-.252.084-.24.108-.444.108-.66V.36Zm1.944 7.872c-1.14 0-1.944-1.056-1.944-2.304 0-1.248.804-2.304 1.944-2.304 1.248 0 1.896 1.056 1.896 2.304 0 1.248-.648 2.304-1.896 2.304Zm3.24-5.376 2.568 6.42-.108.324c-.156.468-.348.84-1.26.84h-.648v.864h.744c1.104 0 1.668-.432 2.088-1.572l2.568-6.876H85.88l-1.668 4.848a1.341 1.341 0 0 0-.084.456c0 .072-.012.156-.096.156s-.096-.084-.096-.156c0-.18-.036-.324-.084-.468L82.04 2.856h-1.056Z"></path></g></g></svg></a></div><div class="style_text__Yppmv"><div><a href="https://twitter.com/synairgenplc" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><path fill="#002158" fill-rule="evenodd" d="M20 0c11.038 0 20 8.962 20 20s-8.962 20-20 20S0 31.038 0 20 8.962 0 20 0Zm-3.523 30.637c8.85 0 13.69-7.333 13.69-13.689 0-.21 0-.419-.01-.619a9.856 9.856 0 0 0 2.404-2.494 9.764 9.764 0 0 1-2.764.758 4.809 4.809 0 0 0 2.116-2.664 9.744 9.744 0 0 1-3.053 1.168 4.788 4.788 0 0 0-3.513-1.517 4.812 4.812 0 0 0-4.809 4.81c0 .378.04.748.13 1.097a13.648 13.648 0 0 1-9.918-5.029 4.826 4.826 0 0 0-.648 2.415 4.79 4.79 0 0 0 2.145 4 4.726 4.726 0 0 1-2.175-.598v.06a4.817 4.817 0 0 0 3.861 4.72c-.4.11-.828.169-1.267.169-.31 0-.609-.03-.908-.09a4.804 4.804 0 0 0 4.49 3.343 9.671 9.671 0 0 1-7.124 1.985 13.405 13.405 0 0 0 7.353 2.175Z"></path></svg></a><a href="https://www.linkedin.com/company/synairgen-research-ltd" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><path fill="#002158" fill-rule="evenodd" d="M20 0c11.038 0 20 8.962 20 20s-8.962 20-20 20S0 31.038 0 20 8.962 0 20 0Zm-6.253 31.24V15.62H8.555V31.24h5.192Zm18.72 0v-8.957c0-4.797-2.561-7.03-5.977-7.03-2.754 0-3.988 1.516-4.679 2.58V15.62h-5.19c.068 1.465 0 15.619 0 15.619h5.19v-8.723c0-.467.034-.933.171-1.267.375-.932 1.23-1.898 2.664-1.898 1.878 0 2.63 1.432 2.63 3.531v8.357h5.191ZM11.186 8.09c-1.777 0-2.937 1.168-2.937 2.699 0 1.498 1.125 2.698 2.868 2.698h.034c1.81 0 2.937-1.2 2.937-2.698-.033-1.531-1.127-2.7-2.902-2.7Z"></path></svg></a></div><div><a href="/cookie-policy">Cookie Policy</a><a href="/legal-notice">Legal</a><a href="/privacy-policy">Privacy Policy</a><div class="style_copy__psYPW">© Synairgen plc. All Rights Reserved<small>Registered in England and Wales No. 5233429 | <a href="https://ethercreative.co.uk">Site by Ether</a></small></div></div></div></div></div></footer></div><script id="__NEXT_DATA__" type="application/json">{"props":{"headerNav":[{"id":"14869","uri":"","title":"Home","children":[]},{"id":"1054","uri":"about","title":"About","children":[{"type":"craft\\elements\\Entry","id":"1055","uri":"about","title":"Our Story"},{"type":"craft\\elements\\Entry","id":"1056","uri":"about/team","title":"Meet the Team"},{"type":"craft\\elements\\Entry","id":"14870","uri":"faqs","title":"FAQs"}]},{"id":"1057","uri":"science","title":"Our Science","children":[{"type":"craft\\elements\\Entry","id":"14871","uri":"science","title":"Inhaled IFN-β"},{"type":"craft\\elements\\Entry","id":"5511","uri":"science/programmes","title":"Clinical Trials"},{"type":"craft\\elements\\Entry","id":"1779","uri":"ifn-beta-publication-list","title":"Publications"}]},{"id":"1059","uri":"investors","title":"Investors","children":[{"type":"craft\\elements\\Entry","id":"1061","uri":"investors/performance","title":"Share Price Information"},{"type":"craft\\elements\\Entry","id":"1062","uri":"investors/presentations","title":"Reports \u0026 Presentations"},{"type":"craft\\elements\\Entry","id":"1063","uri":"investors/investor-news","title":"Investor News"},{"type":"craft\\elements\\Entry","id":"1064","uri":"investors/analysts","title":"Shareholder Information"},{"type":"craft\\elements\\Entry","id":"5261","uri":"investors/aim-rule-26","title":"AIM Rule 26"},{"type":"craft\\elements\\Entry","id":"5262","uri":"investors/corporate-governance-statement","title":"Corporate Governance"},{"type":"craft\\elements\\Entry","id":"14872","uri":"investors/investor-calendar","title":"Investor Calendar"},{"type":"b\\nodeTypes\\StockInfo","id":"1069","uri":"","title":"Stock Info"}]},{"id":"1067","uri":"media","title":"News","children":[{"type":"craft\\elements\\Entry","id":"4878","uri":"media#press","title":"Press Releases"},{"type":"craft\\elements\\Entry","id":"14873","uri":"media/resources","title":"Resources"},{"type":"craft\\elements\\Entry","id":"14874","uri":"media/resources#factsheets","title":"Factsheets"},{"type":"craft\\elements\\Entry","id":"6452","uri":"investors/tr1","title":"TR-1/Options Press Releases"}]},{"id":"1065","uri":"careers","title":"Careers","children":[]},{"id":"1066","uri":"contact","title":"Contact","children":[]}],"footerPagesNav":[{"id":"7882","uri":"cookie-policy","title":"Cookie Policy"},{"id":"1122","uri":"legal-notice","title":"Legal"},{"id":"1123","uri":"privacy-policy","title":"Privacy Policy"}],"footerNav":[{"id":"1292","title":"Our Science","children":[{"id":"1293","uri":"science","title":"Interferon Beta"},{"id":"1852","uri":"science/covid-19","title":"Investigating antiviral treatment in COVID-19"},{"id":"1853","uri":"science/copd","title":"Investigating antiviral treatment in COPD"},{"id":"1854","uri":"science/asthma","title":"Investigating antiviral treatment in asthma"},{"id":"1855","uri":"ifn-beta-publication-list","title":"Relevant Publications"}]},{"id":"1863","title":"About","children":[{"id":"14875","uri":"","title":"Home"},{"id":"1866","uri":"about","title":"Our Story"},{"id":"1867","uri":"about/team","title":"Team"},{"id":"14876","uri":"faqs","title":"FAQs"},{"id":"1868","uri":"careers","title":"Careers"},{"id":"1869","uri":"contact","title":"Contact"}]},{"id":"1856","title":"Investors","children":[{"id":"1871","uri":"investors","title":"Investors Overview"},{"id":"1858","uri":"investors/performance","title":"Performance"},{"id":"1859","uri":"investors/presentations","title":"Reports \u0026 Presentations"},{"id":"1860","uri":"investors/investor-news","title":"Investor News"},{"id":"1870","uri":"investors/analysts","title":"Analysts"},{"id":"14877","uri":"investors/investor-calendar","title":"Investor Calendar"}]},{"id":"1862","title":"News","children":[{"id":"1864","uri":"media#press","title":"Press Releases"},{"id":"14879","uri":"media/resources#factsheets","title":"Factsheets"},{"id":"1865","uri":"media/resources","title":"Resources"}]}],"pageProps":{"seo":{"title":"Breakthrough Science for Severe Viral Lung Infections - Synairgen","description":"Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. Discover SNG001, our breakthrough treatment for COVID-19.","social":{"twitter":{"title":"Breakthrough Science for Severe Viral Lung Infections - Synairgen","description":"Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. Discover SNG001, our breakthrough treatment for COVID-19.","image":null},"facebook":{"title":"Breakthrough Science for Severe Viral Lung Infections - Synairgen","description":"Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. Discover SNG001, our breakthrough treatment for COVID-19.","image":null}}},"hero":[{"image":[{"url":"https://synairgen.ams3.digitaloceanspaces.com/_1520x1480_crop_center-center_none/synairgen-lung-illustration.svg","wide":"https://synairgen.ams3.digitaloceanspaces.com/_3600x1480_crop_center-center_none/synairgen-lung-illustration.svg","raw":"https://synairgen.ams3.digitaloceanspaces.com/synairgen-lung-illustration.svg","mimeType":"image/svg+xml","credit":null}],"preHeading":null,"heading":"Breakthrough Science for Severe Viral Lung Infections","text":"We are a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta (IFN-β) for the treatment of severe viral lung infections as potentially the first host-directed, broad-spectrum antiviral treatment delivered directly into the lungs.","primaryCta":{"children":"Our Science","href":"https://synairgen.vercel.app/science","elementType":"url","target":null,"element":null},"secondaryCta":{"children":"Our Story","href":"https://craft.synairgen.com/about","elementType":"entry","target":null,"element":{"title":"Story","uri":"about"}}}],"blocks":[{"key":"13862","typeHandle":"videoGrid","heading":"Not All Antivirals Are the Same","text":"\u003ch3\u003eHost Directed, broad-spectrum antivirals\u003cbr /\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cstrong\u003eHost Directed\u003c/strong\u003e is Synairgen's new podcast series that explores the need for broad-spectrum antivirals to treat severe respiratory infections. In Episode 1, \u003cem\u003eNot All Antivirals Are the Same\u003c/em\u003e, Professor Tom Wilkinson from the University of Southampton and Vicki Tear, Vice President, Non-Clinical Operations, Synairgen, discuss how antiviral agents work on viruses and the potential benefits of broad-spectrum host-directed antivirals. Episode 2 includes Professor Ratko Djukanovic, Professor of Medicine at University of Southampton and Richard Marsden, CEO of Synairgen, continuing the discussion with a focus on understanding the broad-spectrum antiviral protein, IFN-β.\u003c/p\u003e","videos":[{"id":"13863","videoId":"YP5AzQnETm0","poster":[{"url":"https://synairgen.ams3.digitaloceanspaces.com/_2320x1305_crop_center-center_none/host-directed-ep-1.jpg"}],"caption":"\u003cp\u003eEpisode 1: Not All Antivirals Are the Same\u003c/p\u003e\n\u003cp\u003eProfessor Tom Wilkinson from the University of Southampton and Vicki Tear, Vice President, Non-Clinical Operations, Synairgen, discuss how antiviral agents work on viruses and the potential benefits of broad-spectrum host-directed antivirals.\u003c/p\u003e"},{"id":"13864","videoId":"DaTZqkJJEnI","poster":[{"url":"https://synairgen.ams3.digitaloceanspaces.com/_2320x1305_crop_center-center_none/Synairgen-HD-Podcast2.jpg"}],"caption":"\u003cp\u003eEpisode 2: What is IFN-β and How Does It Work?\u003c/p\u003e\n\u003cp\u003eProfessor Ratko Djukanovic, Professor of Medicine at University of Southampton and Richard Marsden, CEO of Synairgen, continue to explore antivirals with a discussion focused on understanding the broad-spectrum antiviral protein, IFN-β .\u003c/p\u003e"}]},{"key":"14569","typeHandle":"need","heading":"The Need","overview":"\u003cp\u003eViruses that cause severe respiratory infections (VRIs) lead to the hospitalisation of more than 3 million people in the US alone each year.\u003c/p\u003e","text":"\u003cp\u003eThere are currently no broad-spectrum antivirals approved for use in patients who become hospitalised with these sRVIs including SARS-CoV-2, complicated influenza, RSV, adenovirus, parainfluenza and rhinoviruses.\u003c/p\u003e\n\u003cp\u003e\u003csub\u003esource: IQVIA\u003c/sub\u003e\u003c/p\u003e","stats":[{"id":"14570","icon":[{"url":"https://synairgen.ams3.digitaloceanspaces.com/hospital_2022-12-06-075007_bspm.svg","svg":"\u003csvg width=\"48px\" height=\"52px\" viewBox=\"0 0 48 52\" version=\"1.1\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"\u003e\u003ctitle\u003ehospital\u003c/title\u003e\u003cg id=\"Q4—2022\" stroke=\"none\" stroke-width=\"1\" fill=\"none\" fill-rule=\"evenodd\"\u003e\u003cg id=\"Home\" transform=\"translate(-870.000000, -2308.000000)\" stroke=\"#0160FD\" stroke-width=\"3\"\u003e\u003cg id=\"hospital\" transform=\"translate(872.000000, 2310.000000)\"\u003e\u003cpolygon id=\"Path\" points=\"0 18.0488795 22.0000238 0 44 18.0488795 44 48 0 48\"\u003e\u003c/polygon\u003e\u003cline x1=\"32.6163853\" y1=\"29.2540988\" x2=\"11.3831872\" y2=\"29.2540988\" id=\"Path\"\u003e\u003c/line\u003e\u003cline x1=\"22.0002613\" y1=\"39.9709065\" x2=\"22.0002613\" y2=\"18.5371472\" id=\"Path\"\u003e\u003c/line\u003e\u003c/g\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e"}],"stat":"Estimated 3m+","text":"people in US hospitalised annually from 2022 onwards due to severe VRIs","source":"source: IQVIA market research Q4 2022; Sources: US CDC, HCUP, IQVIA Claims Data, PubMed; data on file"},{"id":"14571","icon":[{"url":"https://synairgen.ams3.digitaloceanspaces.com/lungs_2022-12-06-075028_xedg.svg","svg":"\u003csvg width=\"52px\" height=\"50px\" viewBox=\"0 0 52 50\" version=\"1.1\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"\u003e\u003ctitle\u003elungs\u003c/title\u003e\u003cg id=\"Q4—2022\" stroke=\"none\" stroke-width=\"1\" fill=\"none\" fill-rule=\"evenodd\"\u003e\u003cg id=\"Home\" transform=\"translate(-1199.000000, -2310.000000)\" stroke=\"#0160FD\" stroke-width=\"3\"\u003e\u003cg id=\"lungs\" transform=\"translate(1201.002512, 2310.000000)\"\u003e\u003cpath d=\"M0.000445025429,43.7897796 C-0.0439200106,44.9518565 3.24098418,48.0846853 4.39939856,47.9850826 L16.6363357,46.7327534 C17.7363436,46.6037025 20.356048,43.1496118 20.1838789,42.0553036 L19.0757934,34.4912349 C18.1436938,28.1280108 17.4536619,21.7362614 17.0056976,15.3159868 C16.9406957,13.950183 12.3528409,11.3403905 11.145991,11.9827038 C3.13063018,16.5683161 0.403195515,27.438534 0.000445025429,43.7897796 Z\" id=\"Path\"\u003e\u003c/path\u003e\u003cpolyline id=\"Path\" points=\"23.9985312 0 23.9985312 17.7413311 6.26081533 31.3082314\"\u003e\u003c/polyline\u003e\u003cline x1=\"12.1726917\" y1=\"26.7852356\" x2=\"8.34760544\" y2=\"22.9593697\" id=\"Path\"\u003e\u003c/line\u003e\u003cline x1=\"10.4156144\" y1=\"28.1294023\" x2=\"12.5211856\" y2=\"33.3954468\" id=\"Path\"\u003e\u003c/line\u003e\u003cpolyline id=\"Path\" points=\"10.4343955 36.52627 12.5211856 33.3954468 14.6079757 34.4390545\"\u003e\u003c/polyline\u003e\u003cpath d=\"M36.8510715,11.9827038 C44.8768662,16.5745777 47.5938669,27.438534 47.9945306,43.7897796 C48.0388956,44.9518565 44.7539915,48.0846853 43.5955771,47.9850826 L31.3586399,46.7327534 C30.2586321,46.6037025 27.6389277,43.1496118 27.8110967,42.0553036 L28.9191823,34.4912349 C29.8512819,28.1280108 30.5413138,21.7362614 30.9892781,15.3159868 C31.0539371,13.9495635 35.6440611,11.3394096 36.8510715,11.9827038 Z\" id=\"Path\"\u003e\u003c/path\u003e\u003cline x1=\"23.9985312\" y1=\"17.7413311\" x2=\"41.7362471\" y2=\"31.3082314\" id=\"Path\"\u003e\u003c/line\u003e\u003cline x1=\"35.8243707\" y1=\"26.7852356\" x2=\"39.649457\" y2=\"22.9593697\" id=\"Path\"\u003e\u003c/line\u003e\u003cline x1=\"37.581448\" y1=\"28.1294023\" x2=\"35.4758768\" y2=\"33.3954468\" id=\"Path\"\u003e\u003c/line\u003e\u003cpolyline id=\"Path\" points=\"37.5626669 36.52627 35.4758768 33.3954468 33.3890867 34.4390545\"\u003e\u003c/polyline\u003e\u003c/g\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e"}],"stat":"7m immuno-compromised","text":"in the US, representing a population at significant risk for severe RVIs","source":"source: American Medical Association"},{"id":"14572","icon":[{"url":"https://synairgen.ams3.digitaloceanspaces.com/dollar_2022-11-22-104831_dygf_2022-12-06-075025_rnmr.svg","svg":"\u003csvg width=\"28px\" height=\"52px\" viewBox=\"0 0 28 52\" version=\"1.1\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"\u003e\u003ctitle\u003edollar\u003c/title\u003e\u003cg id=\"Q4—2022\" stroke=\"none\" stroke-width=\"1\" fill=\"none\" fill-rule=\"evenodd\"\u003e\u003cg id=\"Home\" transform=\"translate(-706.000000, -2367.000000)\" stroke=\"#0160FD\" stroke-width=\"3\"\u003e\u003cg id=\"dollar\" transform=\"translate(708.000000, 2369.000000)\"\u003e\u003cpath d=\"M0,34.79688 L0,38.29992 C0,41.00616 2.350512,43.2 5.25,43.2 L18.75,43.2 C21.64944,43.2 24,41.00832 24,38.30232 L24,29.30784 C24,27.13008 22.45992,25.21416 20.22,24.60432 L3.780024,20.12904 C1.540032,19.5192 0,17.602992 0,15.425208 L0,9.69972 C0,6.993504 2.350488,4.8 5.249976,4.8 L18.75,4.8 C21.64944,4.8 24,6.993816 24,9.700008 L24,13.204656\" id=\"Path\"\u003e\u003c/path\u003e\u003cline x1=\"12\" y1=\"48\" x2=\"12\" y2=\"0\" id=\"Path\" stroke-linecap=\"square\"\u003e\u003c/line\u003e\u003c/g\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e"}],"stat":"$50b","text":"The estimated annual US healthcare costs related to severe VRIs","source":"sources: Hartnet J. Influenza Other Respi Viruses. 2022;16:906–915; Pastula ST et.al.,OFID, 2017,ofw270; Zhou JA et.al., CID, 2020, 70(5): 773-779; Disease Burden of Flu | CDC; Preliminary Medicare COVID-19 Data Snapshot (Dec 2021); ICER Report: Special Assessment of Outpatient Treatments for COVID-19 Feb 2022"}]},{"key":"1717","typeHandle":"quotes","heading":null,"text":null,"quotes":[{"key":"1739","quote":"It Ain’t Over Till It’s Over…but It’s Never Over","cite":"Dr. Anthony Fauci, New England Journal of Medicine, 26 November 2022"}]}],"news":[{"key":"23771","uri":"media/exercise-of-share-options-and-total-voting-rights","title":"Exercise of Share Options and Total Voting Rights","postDate":"30th October 2024","pdf":[],"articleContent":[{"__typename":"articleContent_text_BlockType"}]},{"key":"23498","uri":"media/results-of-agm-and-appointment-of-new-chairman-2","title":"Results of AGM and Appointment of New Chairman","postDate":"10th October 2024","pdf":[],"articleContent":[{"__typename":"articleContent_text_BlockType"}]},{"key":"23090","uri":"media/interim-results-3","title":"Interim Results","postDate":"26th September 2024","pdf":[],"articleContent":[{"__typename":"articleContent_text_BlockType"}]}]},"__N_SSG":true},"page":"/","query":{},"buildId":"-x01IBkAo6htgTgKAvdde","isFallback":false,"gsp":true,"appGip":true,"scriptLoader":[]}</script></body></html>